603520.SH
Zhejiang Starry Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 7.98
+2.70%Year over year
Reported trailing growth
- Revenue
- +3.2%
- EBITDA
- —
- EBIT
- +141.1%
- EPS
- +142.1%
- Free cash flow
- -39.5%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.7%
- EBITDA
- +32.2%
- EBIT
- -50.3%
- Net income
- -51.9%
- EPS
- -60.8%
- Free cash flow
- +7.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026